AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional PatentLeading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Common Eye Conditions
AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM’s Eye Diagnostic SolutionsTechnology and Benefits Company At Forefront of Leading Ophthalmological Media Outlets’ Coverage of Innovative Diagnostic Solutions
AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial LaunchHealthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company
AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics’ Commercial Launch at AAO 2022Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership
AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy SeasonSAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface diseases, announced today that it has launched an enhanced version of its rapid Ocular Immunoglobulin E (IgE) test in response to a study recently published in Nature by researchers at the University of Michigan Department of Climate and Space Sciences and Engineering.
